Description: Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Home Page: www.moleculin.com
MBRX Technical Analysis
5300 Memorial Drive
Houston,
TX
77007
United States
Phone:
713 300 5160
Officers
| Name | Title |
|---|---|
| Mr. Walter V. Klemp | Founder, Chairman, Pres & CEO |
| Mr. Jonathan P. Foster CPA | Exec. VP & CFO |
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board |
| Dr. Robert C. Shepard FACP, M.D., F.A.C.P. | Chief Medical Officer of Annamycin |
| Dr. John Paul Waymack M.D., Sc.D. | Sr. Chief Medical Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer of New Products |
| Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. | European Chief Medical Officer |
| Ms. Jacqueline Northcut | Consultant |
| Mr. Louis Ploth Jr. | Independent Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6616 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-06-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |